RCM
ALNY icon

Raleigh Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Raleigh Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2
Closed -$383 – 974
2023
Q4 		$383 Hold
2
– – ﹤0.01% 1010
2023
Q3 		$354 Buy
+2
New +$382 ﹤0.01% 903

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raleigh Capital Management's ALNY Position: Q1 2024 in Review

Raleigh Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2024, closing a stake of 2 shares — an estimated $383 sold.

Raleigh Capital Management first reported a position in ALNY in Q3 2023 and held it in 2 quarters. The position peaked at $383 in Q4 2023. 498 funds tracked by Wall St. Rank hold ALNY as of Q1 2024.

  • Raleigh Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Raleigh Capital Management sold 2 Alnylam Pharmaceuticals shares in Q1 2024, an estimated $383.
  • Raleigh Capital Management first reported a position in Alnylam Pharmaceuticals in Q3 2023 and held it in 2 quarters.
  • Raleigh Capital Management's Alnylam Pharmaceuticals position peaked at $383 in Q4 2023.
  • 498 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2024.

Based on Raleigh Capital Management's 13F filing for Q1 2024, filed 13 May 2024.